Weekly Digest – February 2026 Weekly Digest – February 2026 03 February 2026: Datroway granted priority review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Datroway has taken a […]
Weekly Digest – February 2026 Weekly Digest – February 2026 30 January 2026: Takeda submits new drug application for Mirvetuximab Soravtansine for folate receptor alpha-positive, platinum-resistant recurrent ovarian cancer in Japan Takeda has moved a step closer to expanding treatment […]
Weekly Digest – February 2026 Weekly Digest – February 2026 30 January 2026: Astellas submits Supplemental New Drug Application in Japan for PADCEV™ (Enfortumab vedotin) with Keytruda ® (Pembrolizumab) for certain patients with muscle-invasive bladder cancer Astellas Pharma has advanced […]
Weekly Digest – February 2026 Weekly Digest – February 2026 04 February 2026: The supplemental application for BB-1701 for injection from Bliss Biopharmaceuticals (Hangzhou) has been accepted by NMPA The latest update from China’s drug regulatory system shows progress in […]
